British journal of cancer · 2026
Identification of a distinct cluster of LY6E+ macrophages in esophageal squamous cell carcinoma: functional phenotype, spatial interaction, and prognostic significance.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Chen Kun, Ni Jianjiao, Li Yida, Gu Sijia, Li Ye, Yang Xi, Goswami Shyamal, Luo Qiyu, Zhang Yalei, Qian Ling, Hu Yudi, Zhou Runye, Wang Yating, Liu Jingjing, Cai Xiuyu, Zhang Chunrong, Afridi Saifullah, Chen Yi, Wang Peng, Zhu Zhengfei
Аннотация
BACKGROUND: Tumor-associated macrophages are key players in cancer progression, but their heterogeneity is not fully understood. This study aims to investigate the role of a specific macrophage subpopulation marked by LY6E in esophageal squamous cell carcinoma (ESCC).
METHODS: We analyzed macrophage subsets in ESCC, focusing on LY6E+ populations. Their gene expression signature, functional characteristics, and correlation with patient prognosis and immunotherapy response were assessed through single cell RNA sequencing and multiplex immunohistochemistry.
RESULTS: A distinct LY6E+ macrophage subpopulation was identified, enriched in tumors and associated with poor prognosis. These cells exhibited an M2-like, immunosuppressive phenotype, yet possessed high phagocytic and antigen-presenting potential. A potential niche involving LY6E+ macrophages, exhausted CD8+ T cells, and ICAM2+ tumor cells was discovered, which predicted a better response to immunotherapy.
CONCLUSIONS: Our findings reveal a critical and complex role for LY6E+ macrophages in ESCC, highlighting them as a potential target for therapeutic intervention.
METHODS: We analyzed macrophage subsets in ESCC, focusing on LY6E+ populations. Their gene expression signature, functional characteristics, and correlation with patient prognosis and immunotherapy response were assessed through single cell RNA sequencing and multiplex immunohistochemistry.
RESULTS: A distinct LY6E+ macrophage subpopulation was identified, enriched in tumors and associated with poor prognosis. These cells exhibited an M2-like, immunosuppressive phenotype, yet possessed high phagocytic and antigen-presenting potential. A potential niche involving LY6E+ macrophages, exhausted CD8+ T cells, and ICAM2+ tumor cells was discovered, which predicted a better response to immunotherapy.
CONCLUSIONS: Our findings reveal a critical and complex role for LY6E+ macrophages in ESCC, highlighting them as a potential target for therapeutic intervention.